CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Tianjin Chase Sun Pharmaceutical Company Limited Company Snapshot
Tianjin Chase Sun Pharmaceutical Company Limited operates within the Medicinals and botanicals sector. In addition to historical fundamental analyses, the complete report available to purchase compares Tianjin Chase Sun Pharmaceutical Company Limited with three other companies in this sector in CHINA : Changjiang Runfa Medicine Co Ltd (2019 sales of 5.07 billion Chinese Renmimbi [US$730.35 million] of which 71% was Medicine), Shanxi Zhendong Pharmaceutical Co Ltd (4.40 billion Chinese Renmimbi [US$633.29 million] of which 107% was Medicine Manufacture and Sale), and Shandong Xinhua Pharmaceutical Company Limited (5.61 billion Chinese Renmimbi [US$807.10 million] of which 57% was Preparations).

Sales Analysis. During the year ended December of 2019, sales at Tianjin Chase Sun Pharmaceutical Company Limited were 5.00 billion Chinese Renmimbi (US$720.27 million). This is an increase of 18.4% versus 2018, when the company's sales were 4.22 billion Chinese Renmimbi. Sales of Medical Devices saw an increase that was more than double the company's growth rate: sales were up 146.9% in 2019, from 265.33 million Chinese Renmimbi to 655.06 million Chinese Renmimbi. Tianjin Chase Sun Pharmaceutical Company Limited also saw significant increases in sales in Granules (up 25.2% to 2.71 billion Chinese Renmimbi) and Other Main Operation (up 32.8% to 158.86 million Chinese Renmimbi) . Not all segments of Tianjin Chase Sun Pharmaceutical Company Limited experienced an increase in sales in 2019: sales of Finished Medicine fell 12.5% to 1.06 billion Chinese Renmimbi. Tianjin Chase Sun Pharmaceutical Company Limited also experienced decreases in sales in Excipients and Api (down 9.2% to 422.38 million Chinese Renmimbi) .
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Tianjin Chase Sun Pharmaceutical Company Limited
  Stock Performance Chart for Tianjin Chase Sun Pharmaceutical Company Limited
 
  Stock Data: Recent Stock Performance:
  Current Price (8/7/2020): 5.65
(Figures in Chinese Renmimbi)
1 Week 2.0%   13 Weeks -6.6%  
4 Weeks -3.1%   52 Weeks 77.7%  
 
Tianjin Chase Sun Pharmaceutical Company Limited Key Data:
  Ticker: 300026 Country: China
  Exchanges: SZN Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Medicinals & Botanicals
  2019 Sales 5,002,938,538
(Year Ending Jan 2020).
Employees: 5,493
  Currency: Chinese Renmimbi Market Cap: 16,982,232,329
  Fiscal Yr Ends: December Shares Outstanding: 3,005,704,837
  Share Type: A Gu Closely Held Shares:
 
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.